© 2016 NeuroRx, Inc.

*This drug is investigational and not approved by the US FDA

STAY CONNECTED

Additional Indications

 

NeuroRx has the potential to build a pipeline of novel CNS-focused therapeutics. We believe that our leadership in the science of the N-methyl-D-asparate (NMDA) receptor, and how it may affect various disorders marked by depression, strongly positions us to pursue additional indications.

 

Our initial focus on Acute Suicidal Ideation/Behavior (ASIB) in Bipolar Depression. Thereafter the company plans to expand into ASIB in major depressive disorder (MDD). Other potential indications include chronic depression, post-traumatic stress disorder and bipolar depression marked by a less acute level of suicide risk.

Based on our scientific leadership around the NMDA receptor,

NeuroRx has the

potential to build a

pipeline of novel,

CNS-focused

therapeutics